Lise Cuzin

Summary

Country: France

Publications

  1. pmc Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study
    Karen Champenois
    ATIP Avenir Inserm Modélisation, Aide à la Décision, et Coût Efficacité en Maladies Infectieuses, 152 rue du Professeur Yersin, Loos 59120, France
    BMC Infect Dis 13:200. 2013
  2. doi request reprint Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study
    Lise Cuzin
    Infectious Diseases Department, University Hospital, Toulouse, France
    J Acquir Immune Defic Syndr 61:557-64. 2012
  3. doi request reprint How long do physicians wait to start antiretroviral treatment in newly diagnosed HIV-infected patients?
    Lise Cuzin
    Infectious and Tropical Diseases Unit, Purpan Hospital, Toulouse, France
    HIV Clin Trials 12:339-42. 2011
  4. doi request reprint Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort
    L Cuzin
    CISIH Hôpital Purpan, Toulouse, France
    HIV Clin Trials 9:147-51. 2008
  5. ncbi request reprint Antiviral benefits for HIV-infected patients : the crucial role & multiple determinants of adherence
    L Cuzin
    Centre for Care and Information in Human Immunodeficiency Toulouse, France
    Indian J Med Res 127:7-9. 2008
  6. ncbi request reprint Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years
    Lise Cuzin
    Department of Infectious and Tropical Diseases, Hopital Purpan, Toulouse, France
    Clin Infect Dis 45:654-7. 2007
  7. ncbi request reprint Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients
    L Cuzin
    Centre for Care and Information in Human Immunodeficiency, Toulouse, France
    HIV Med 6:388-95. 2005
  8. ncbi request reprint Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Lise Cuzin
    Infectious Diseases Unit, Purpan University Hospital, Toulouse, France
    AIDS Rev 10:205-11. 2008
  9. pmc Correlates of late HIV diagnosis: implications for testing policy
    Cyrille Delpierre
    INSERM U558, F31073, Toulouse, France
    Int J STD AIDS 18:312-7. 2007
  10. pmc First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load
    Isabelle Poizot-Martin
    aAix Marseille University, APHM Hôpital Sainte Marguerite, Immuno Hematology Clinic bInserm U912 SESSTIM, Marseille cCHU Hotel Dieu, Infectious Diseases Unit, Nantes dInserm eUniversité de Toulouse III, UMR1027, Toulouse fAPHP Necker Hospital, Infectious Diseases Department, Necker Pasteur Infectious Diseases Center, IHU Imagine gPasteur Institut, Medical Care Center, Necker Pasteur Infectious Diseases Center France hUniversité Paris Descartes, Sorbonne Paris Cité, Paris iInfectious Diseases Department, CHU of Nice, University Nice Sophia Antipolis jHôpitaux Universitaires Strasbourg, Center for HIV Care, Strasbourg kHospital Tourcoing, Infectious Disease Unit, Tourcoing lINSERM, UMR 1027, Toulouse III University, Toulouse, F 31000, France CHU Toulouse, COREVIH Toulouse, F 31000 mAP HP, Hospital Pitié Salpêtrière, Department of Infectious Diseases nUPMC Univ Paris oUMRS 943, Paris pCHU de Fort de France, Service de Maladies Infectieuses et Tropicales, Martinique qUniversité des Antilles, Baltimore
    Medicine (Baltimore) 95:e5087. 2016

Collaborators

Detail Information

Publications33

  1. pmc Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study
    Karen Champenois
    ATIP Avenir Inserm Modélisation, Aide à la Décision, et Coût Efficacité en Maladies Infectieuses, 152 rue du Professeur Yersin, Loos 59120, France
    BMC Infect Dis 13:200. 2013
    ..In France, 1/3 HIV-infected patients is diagnosed at an advanced stage of the disease. We describe missed opportunities for earlier HIV testing in newly-HIV-diagnosed patients...
  2. doi request reprint Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study
    Lise Cuzin
    Infectious Diseases Department, University Hospital, Toulouse, France
    J Acquir Immune Defic Syndr 61:557-64. 2012
    ..To address the ability of a 24-week Maraviroc (MVC) intensification of a stable antiretroviral therapy (cART) to significantly increase the CD4 cell count slope...
  3. doi request reprint How long do physicians wait to start antiretroviral treatment in newly diagnosed HIV-infected patients?
    Lise Cuzin
    Infectious and Tropical Diseases Unit, Purpan Hospital, Toulouse, France
    HIV Clin Trials 12:339-42. 2011
    ..With the aim to look for possible ways to reduce individual time from HIV diagnosis to low viraemia and reduced infectivity, we measured time between HIV diagnosis and treatment initiation in a large prospective cohort...
  4. doi request reprint Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort
    L Cuzin
    CISIH Hôpital Purpan, Toulouse, France
    HIV Clin Trials 9:147-51. 2008
    ..To assess virological efficacy of a ritonavir-boosted atazanavir (ATV/r)-containing regimen in patients with persistent viral replication despite HAART...
  5. ncbi request reprint Antiviral benefits for HIV-infected patients : the crucial role & multiple determinants of adherence
    L Cuzin
    Centre for Care and Information in Human Immunodeficiency Toulouse, France
    Indian J Med Res 127:7-9. 2008
  6. ncbi request reprint Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years
    Lise Cuzin
    Department of Infectious and Tropical Diseases, Hopital Purpan, Toulouse, France
    Clin Infect Dis 45:654-7. 2007
    ..Late testing, which was more frequent in the older age group, was the only independent factor associated with immunologic and clinical evolution of infection. Age >50 years was associated with earlier treatment discontinuation...
  7. ncbi request reprint Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients
    L Cuzin
    Centre for Care and Information in Human Immunodeficiency, Toulouse, France
    HIV Med 6:388-95. 2005
    ..Data on the efficacy of this triple nucleoside reverse transcriptase inhibitor (NRTI) combination compared with the gold-standard nonnucleoside reverse transcriptase inhibitor (NNRTI) regimen could provide important information...
  8. ncbi request reprint Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Lise Cuzin
    Infectious Diseases Unit, Purpan University Hospital, Toulouse, France
    AIDS Rev 10:205-11. 2008
    ..In conclusion, protease inhibitor-based and nonnucleoside reverse transcriptase inhibitor-based regimens each have many advantages. The best choice will essentially be made taking into account the patients' characteristics...
  9. pmc Correlates of late HIV diagnosis: implications for testing policy
    Cyrille Delpierre
    INSERM U558, F31073, Toulouse, France
    Int J STD AIDS 18:312-7. 2007
    ..Among migrants, HIV testing with informed consent short after entry should be improved, especially towards individuals not in couple...
  10. pmc First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load
    Isabelle Poizot-Martin
    aAix Marseille University, APHM Hôpital Sainte Marguerite, Immuno Hematology Clinic bInserm U912 SESSTIM, Marseille cCHU Hotel Dieu, Infectious Diseases Unit, Nantes dInserm eUniversité de Toulouse III, UMR1027, Toulouse fAPHP Necker Hospital, Infectious Diseases Department, Necker Pasteur Infectious Diseases Center, IHU Imagine gPasteur Institut, Medical Care Center, Necker Pasteur Infectious Diseases Center France hUniversité Paris Descartes, Sorbonne Paris Cité, Paris iInfectious Diseases Department, CHU of Nice, University Nice Sophia Antipolis jHôpitaux Universitaires Strasbourg, Center for HIV Care, Strasbourg kHospital Tourcoing, Infectious Disease Unit, Tourcoing lINSERM, UMR 1027, Toulouse III University, Toulouse, F 31000, France CHU Toulouse, COREVIH Toulouse, F 31000 mAP HP, Hospital Pitié Salpêtrière, Department of Infectious Diseases nUPMC Univ Paris oUMRS 943, Paris pCHU de Fort de France, Service de Maladies Infectieuses et Tropicales, Martinique qUniversité des Antilles, Baltimore
    Medicine (Baltimore) 95:e5087. 2016
    ..Our data highlight the fact that cART regimens have differential effects on CD8 pool down regulation...
  11. pmc Routine testing to reduce late HIV diagnosis in France
    Cyrille Delpierre
    INSERM U558 F 31073, Toulouse, France
    BMJ 334:1354-6. 2007
  12. doi request reprint Decrease of mitochondrial DNA level in sperm from patients infected with human immunodeficiency virus-1 linked to nucleoside analogue reverse transcriptase inhibitors
    Lynda Pavili
    Universite de Toulouse, UPS, Groupe de Recherche en Fertilité Humaine EA 3694, Human Fertility Research Group, TSA 70034, CECOS Midi Pyrénées, Hôpital Paule de Viguier, Toulouse, France
    Fertil Steril 94:2151-6. 2010
    ..To study sperm parameters in patients infected with human immunodeficiency virus (HIV)-1 and to analyze mitochondrial DNA (mtDNA) in sperm according to the HIV treatment...
  13. doi request reprint No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy
    Stéphanie Raymond
    aINSERM, UMR1043 bUniversité Toulouse III Paul Sabatier, Faculté de Médecine Toulouse Purpan cCHU de Toulouse, Hopital Purpan, Laboratoire de Virologie dINSERM, UMR1027 eUniversité de Toulouse III fCHU Toulouse, COREVIH gCHU de Toulouse, Hopital Purpan, Service des Maladies Infectieuses et Tropicales, Toulouse, France
    AIDS 30:965-8. 2016
    ..The mean CXCR4-using virus frequency in peripheral blood mononuclear cells was 59% before maraviroc intensification and 52% after 24 weeks of effective treatment, indicating no selection by maraviroc. ..
  14. doi request reprint Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?
    Momory Keita
    a Inserm, UMR1027 INSERM Université de Toulouse III, Toulouse, France
    AIDS Care 26:1058-69. 2014
    ....
  15. doi request reprint Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study
    Alain Makinson
    Infectious Diseases Department, CHRU Montpellier, Montpellier, France
    J Thorac Oncol 6:1022-9. 2011
    ..To describe factors associated with survival in human immunodeficiency virus (HIV)-infected subjects with non-small cell lung cancer (NSCLC) and analyze toxicities induced by cytotoxic chemotherapy and antiretroviral compounds...
  16. doi request reprint Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism
    Stéphanie Raymond
    INSERM, U563, Universite Toulouse III Paul Sabatier, Faculté de Médecine Toulouse Purpan, CHU de Toulouse, Hopital Purpan, Laboratoire de Virologie, Toulouse, France
    AIDS 22:F11-6. 2008
    ..Replacing phenotypic assays with simple genotypic predictions of HIV-1 coreceptor usage would make the clinical use of CCR5 antagonists easier...
  17. doi request reprint Prisoners and skin diseases in Toulouse, France: epidemiological analysis and evaluation of life impact
    P Bayle
    Department of Legal and Penitentiary Medicine, Paul Sabatier University and Rangueil Hospital, Toulouse, France
    J Eur Acad Dermatol Venereol 23:52-7. 2009
    ..Dermatology in a penitentiary environment is an under-researched field...
  18. ncbi request reprint Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people
    C Delpierre
    INSERM U558, IFR126, Toulouse, F 31073, France
    Eur J Public Health 18:345-7. 2008
    ..This population is mainly diagnosed late with major consequences on morbidity and mortality...
  19. doi request reprint Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease's lymphadenitis
    Camille Garnier
    Department of Infectious and Tropical Diseases, Toulouse University Hospital, Place du Docteur Baylac TSA 40031, 31059, Toulouse Cedex 9, France
    Infection 44:23-7. 2016
    ..The objective of this study was to evaluate the benefit of an intra-nodal injection of gentamicin add-on oral azithromycin treatment on the outcome of suppurated CSD's lymphadenitis...
  20. pmc Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach
    Lise Cuzin
    From the INSERM, UMR 1027, Toulouse, France Université de Toulouse III, Toulouse, France CHU Toulouse, COREVIH Toulouse, France LC Infectious Diseases Dpt, CHU Archet, Nice, France PP Infectious Diseases Dpt, CHU Hotel Dieu, Nantes, France CA Sorbonne University UPMC Univ Paris 06 UMR_S 1136 Pierre Louis Institute of Epidemiology and Public Health AP HP, Groupe Hospitalier Pitie Salpetriere, Service des Maladies Infectieuses, Paris, France CK Infectious Diseases Dpt, Hospices Civils de Lyon, Lyon, France and INSERM U1052, Lyon, France LC Université Paris Descartes, Sorbonne Paris Cité, Paris, Infectious Diseses Dpt, Tourcoing, France AC Infectious Diseases Dpt, and Université Antilles Guyane, CHU de Martinique, France AC Le Trait d Union, HIV care center, CHU Strasbourg, France DR UMR CNRS 6249 Chrono Environnement, Université de Franche Comté Service de maladies infectieuses, CHRU Besançon, Department of Biology and Psychology
    Medicine (Baltimore) 94:e1668. 2015
    ..Using data from a large prospective cohort, we found that boosted atazanavir and darunavir had comparable effectiveness, whatever the associated NRTIs, whereas efavirenz-based regimens were relatively less performing on the short term...
  21. pmc Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia
    Amélie Chabrol
    Department of Infectious Diseases, Toulouse University Hospital, Toulouse, France
    Haematologica 95:996-1003. 2010
    ..This study assessed the impact of voriconazole or caspofungin prophylaxis in patients undergoing induction chemotherapy for acute leukemia in a hematology unit exposed to building work...
  22. ncbi request reprint [Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological and virological consequences]
    A Sommet
    Centre d information et de soins de l immunodéficience humaine de Midi Pyrénées, Hopital Purpan, 31059 cedex, Toulouse, France
    Rev Med Interne 24:350-7. 2003
    ..This retrospective study analyses causes as well as clinical, immunological and virological consequences of antiretroviral treatment interruptions (Ti) of more than 30 days in HIV-1 infected adults...
  23. doi request reprint Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?
    Philippe Flandre
    aINSERM, UMR S 1136 and Sorbonne Universities, UPMC University of Paris 06, Pierre Louis Institute of Epidemiology and Public Health, ParisbDepartment of Infectious Diseases, CHU Archet, NicecDepartment of Infectious Diseases, CHU Hotel Dieu, NantesdDepartment of Nephrology, Pitie Salpetriere Hospital APHP and Pierre et Marie Curie University, PariseRegional Center for HIV Care and Coordination, Inserm UMR1027, Toulouse 3 University, Toulouse, France
    AIDS 30:1433-8. 2016
    ..We used the D:A:D risk score for chronic kidney disease (CKD) for patients starting antiretroviral therapy (ART) in the recent years, and investigated whether specific regimens enhanced the risk of CKD in the different risk groups...
  24. doi request reprint Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?
    David Metsu
    Laboratoire de Pharmacocinétique et de Toxicologie, Institut Fédératif de Biologie Purpan, Centre Hospitalier Universitaire, Toulouse, France
    Fundam Clin Pharmacol . 2016
    ..17 for Cu ). Neither total nor unbound concentrations of ATV fully explained hyperbilirubinaemia or virologic failure. From this study, we conclude that unbound ATV did not appear to be more relevant than Ct ...
  25. doi request reprint [Use of Nadis(®) software to improve adverse drug reaction reporting of antiretroviral drugs: experience in south west of France (midi-pyrénées)]
    Liselotte Pochard
    Service de Pharmacologie Medicale et Clinique, centre Midi Pyrénées de pharmacovigilance, de Pharmacoépidémiologie et d Information sur le Médicament, CHU Toulouse, INSERM U1027, Universite Toulouse III, Toulouse, France
    Therapie 69:149-55. 2014
    ..To study the value of the module of pharmacovigilance in Nadis® to improve the antiretroviral (ARV) drugs-induced adverse drug reactions (ADRs) reporting...
  26. ncbi request reprint [Analysis of antiretroviral drugs-induced adverse effects]
    Magalie Baudrant
    Service de Pharmacologie Clinique, centre Midi Pyrénées de pharmacovigilance, de Pharmacoepidemiologie et d Informations sur le Medicament, Centre Hospitalier Universitaire, Faculte de Medecine, Toulouse, France
    Therapie 61:171-6. 2006
    ..6% of cases and required the withdrawal of suspected drugs in 57% of cases. Our data show an improvement of antiretroviral drug-induced ADRs reporting...
  27. ncbi request reprint A systematic review of computer-based patient record systems and quality of care: more randomized clinical trials or a broader approach?
    Cyrille Delpierre
    Centre Hospitalo Universitaire Purpan, Service des Maladies Infectieuses et Tropicales, Toulouse, France
    Int J Qual Health Care 16:407-16. 2004
    ..To analyse the impact of computer-based patient record systems (CBPRS) on medical practice, quality of care, and user and patient satisfaction...
  28. ncbi request reprint Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohort
    Charlotte Lewden
    INSERM U330, Bordeaux, France
    J Infect Dis 186:710-4. 2002
    ..Thus, social context plus clinical and biologic data, including the 4-month response to treatment, must be considered in treatment of HIV-infected patients...
  29. ncbi request reprint An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patients
    Charlotte Lewden
    INSERM U593 exU330, Bordeaux, France
    HIV Clin Trials 5:224-31. 2004
    ..To describe information bias due to missing data for hepatitis C (HCV) status in the analysis of factors associated with mortality in HIV-infected patients...
  30. pmc Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy
    Pierre Delobel
    Laboratoire de Virologie EA2046 IFR30, Centre Hospitalier Universitaire, TSA 40031, 31059 Toulouse Cedex 9, France
    J Virol 80:10229-36. 2006
    ..X4 viruses could play a role in the depletion of naïve T cells in poor immunological responders to HAART by triggering persistent T-cell activation and bystander apoptosis via gp120-CXCR4 interactions...
  31. ncbi request reprint High-Risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population
    Cyrille Delpierre
    INSERM U558, Toulouse, F 31073 France
    AIDS Patient Care STDS 20:838-47. 2006
    ..It seems necessary to improve HIV testing policy in the heterosexual population...
  32. ncbi request reprint Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy
    Xavier Duval
    Laboratoire de Recherche en Pathologie Infectieuse, Faculte Xavier Bichat, Paris, France
    Clin Infect Dis 39:248-55. 2004
    ..7; 95% CI, 1.2-2.4) were independently predictive of a SADR. SADRs were frequent in the first 4 months after initiation of highly active antiretroviral therapy but continued to occur after that time period...
  33. ncbi request reprint Enfuvirtide for prophylaxis against HIV infection
    Lise Cuzin
    N Engl J Med 349:2169-70; author reply 2169-70. 2003